Novartis Forging Ahead: Exforge Gets Full Approval, To Launch By End Of June
Executive Summary
Novartis will launch its hypertension treatment Exforge by the end of the month following FDA final approval of the product. The drug is the first to combine an angiotensin receptor blocker, Novartis' Diovan (valsartan), with a calcium channel blocker, Pfizer's Norvasc (amlodipine)
You may also be interested in...
Novartis Gets By With A Little Help From Its Hypertension Franchise
Novartis is still counting on the strength of its pipeline and upcoming product launches to carry the firm through a period of slow growth despite the detrimental impact of the suspension of Zelnorm marketing and the entry of generic competition for Lotrel, the firm stressed during its July 17 second quarter earnings call
Novartis Gets By With A Little Help From Its Hypertension Franchise
Novartis is still counting on the strength of its pipeline and upcoming product launches to carry the firm through a period of slow growth despite the detrimental impact of the suspension of Zelnorm marketing and the entry of generic competition for Lotrel, the firm stressed during its July 17 second quarter earnings call
Will Novartis’ Tekturna Be Buoyed By Category Captainship?
The performance of Novartis' newly approved hypertension therapy Tekturna will be a good test of the company's "category captainship" program, which has focused on establishing Novartis as a leader in targeted disease areas